Invention Application
- Patent Title: NEUTRALIZING ANTI-SARS-COV-2 HUMAN ANTIBODIES
-
Application No.: PCT/EP2022/080965Application Date: 2022-11-07
-
Publication No.: WO2023079137A1Publication Date: 2023-05-11
- Inventor: GEUKENS, Nick , DECLERCK, Paul , IMBRECHTS, Maya , AMPOFO, Louanne , MAES, Wim , NEYTS, Johan , ABDELNABI, Rana , EECKHAUT, Hannah , CALLEWAERT, Nico , FIJALKOWSKA, Daria
- Applicant: KATHOLIEKE UNIVERSITEIT LEUVEN , VIB VZW , UNIVERSITEIT GENT
- Applicant Address: KU Leuven R & D Waaistraat 6 - box 5105; Rijvisschestraat 120; Sint-Pietersnieuwstraat 25
- Assignee: KATHOLIEKE UNIVERSITEIT LEUVEN,VIB VZW,UNIVERSITEIT GENT
- Current Assignee: KATHOLIEKE UNIVERSITEIT LEUVEN,VIB VZW,UNIVERSITEIT GENT
- Current Assignee Address: KU Leuven R & D Waaistraat 6 - box 5105; Rijvisschestraat 120; Sint-Pietersnieuwstraat 25
- Priority: EP21206787.0 2021-11-05
- Main IPC: C07K16/10
- IPC: C07K16/10 ; A61K39/395 ; A61P31/14 ; C12N15/13 ; A61K2039/505 ; A61K2039/53 ; C07K2317/21 ; C07K2317/34 ; C07K2317/56 ; C07K2317/565 ; C07K2317/76 ; C07K2317/92
Abstract:
The invention relates to antibodies or antigen binding fragments thereof, specifically binding to the trimeric spike protein of Wuhan Covid-SARS-2 and specifically binding to the RBD domain of all of Wuhan, alpha, beta, gamma, delta and omicron variant of Covid-SARS-2 spike protein, characterized in that said antibody or antigen binding fragment thereof has an IC50 in a SARS-CoV-2 pseudovirus infection lower than 1 nm in a SARS-CoV-2 pseudovirus infection, and in that said antibody or antigen binding fragment thereof has an affinity for RBD domain Wuhan Covid-SARS-2 spike protein with a KD of less than 500 pM, and in that said antibody or antigen binding fragment thereof has an affinity for trimeric spike protein of Wuhan Covid-SARS-2 with a KD of less than 300 pM.
Information query